Verrica Pharmaceuticals (NASDAQ:VRCA) announces that its new drug application for a proprietary topical therapy for the treatment of molluscum contagiosum has been accepted by the FDA.
The company says the PDUFA goal date assigned by the FDA for the NDA on VP-102 is July 13, 2020.
Management calls the acceptance of the NDA for review the next step toward bringing patients and their caregivers a safe and effective topical therapy for the common, highly contagious viral skin disease.
Source: Press Release
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.